Comparative Pharmacology
Head-to-head clinical analysis: ESGIC PLUS versus SODIUM BUTABARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESGIC PLUS versus SODIUM BUTABARBITAL.
ESGIC-PLUS vs SODIUM BUTABARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esgic-Plus is a combination of acetaminophen (analgesic/antipyretic via COX inhibition and central action), butalbital (barbiturate that enhances GABA-A receptor activity), and caffeine (adenosine receptor antagonist and CNS stimulant). The mechanism for treating tension headache is attributed to the synergistic effects of these components.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression.
1-2 capsules (acetaminophen 500 mg, butalbital 50 mg, caffeine 40 mg per capsule) orally every 4 hours as needed, not exceeding 6 capsules per day.
50-100 mg orally or intramuscularly 3-4 times daily as a sedative; 100-200 mg orally or intramuscularly for preoperative sedation.
None Documented
None Documented
Butalbital: 35-70 hours in adults; prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours in adults; extended in overdose (potential hepatotoxicity). Caffeine: 3-6 hours in adults; increased in pregnancy or liver disease.
Terminal elimination half-life 40-60 hours in adults; prolonged in hepatic impairment and elderly.
Butalbital: 60-90% renal as unchanged drug and metabolites, 10-40% fecal via biliary elimination. Acetaminophen: ~85% renal as glucuronide (45-55%), sulfate (25-35%), and cysteine conjugates (4-15%); 2-4% unchanged. Caffeine: ~85-90% renal as metabolites (1-methylxanthine, 1-methyluric acid, 1,7-dimethylxanthine); 1-3% unchanged.
Renal excretion of unchanged drug and metabolites; approximately 30-50% as unchanged drug in urine. Minor fecal elimination (<5%).
Category C
Category C
Barbiturate/Narcotic Combination
Barbiturate